Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

T helper 17.1 cells associate with multiple sclerosis disease activity: perspectives for early intervention
Jamie van Langelaar, Roos M. van der Vuurst de Vries, Malou Janssen, et al.
Brain (2018) Vol. 141, Iss. 5, pp. 1334-1349
Open Access | Times Cited: 189

Showing 1-25 of 189 citing articles:

Multiple sclerosis
Massimo Filippi, Amit Bar‐Or, Fredrik Piehl, et al.
Nature Reviews Disease Primers (2018) Vol. 4, Iss. 1
Closed Access | Times Cited: 1054
B and T Cells Driving Multiple Sclerosis: Identity, Mechanisms and Potential Triggers
Jamie van Langelaar, Liza Rijvers, Joost Smolders, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 229
The role of TH17 cells in multiple sclerosis: Therapeutic implications
Tobias Moser, Katja Akgün, Undine Proschmann, et al.
Autoimmunity Reviews (2020) Vol. 19, Iss. 10, pp. 102647-102647
Closed Access | Times Cited: 212
T Helper Cells: The Modulators of Inflammation in Multiple Sclerosis
Martina Kunkl, Simone Frascolla, Carola Amormino, et al.
Cells (2020) Vol. 9, Iss. 2, pp. 482-482
Open Access | Times Cited: 188
A role for Th1-like Th17 cells in the pathogenesis of inflammatory and autoimmune disorders
Alí N. Kamali, Seyedeh Masoomeh Noorbakhsh, Haleh Hamedifar, et al.
Molecular Immunology (2018) Vol. 105, pp. 107-115
Closed Access | Times Cited: 166
Targeting toll-like receptor 4 to modulate neuroinflammation in central nervous system disorders
Gunnar R. Leitner, Tyler J. Wenzel, Nick Marshall, et al.
Expert Opinion on Therapeutic Targets (2019) Vol. 23, Iss. 10, pp. 865-882
Closed Access | Times Cited: 165
Choroid Plexus Enlargement in Inflammatory Multiple Sclerosis: 3.0-T MRI and Translocator Protein PET Evaluation
Vito A. G. Ricigliano, Emanuele Morena, Annalisa Colombi, et al.
Radiology (2021) Vol. 301, Iss. 1, pp. 166-177
Open Access | Times Cited: 131
Intrinsic blood–brain barrier dysfunction contributes to multiple sclerosis pathogenesis
Hideaki Nishihara, Sylvain Perriot, Benjamin D. Gastfriend, et al.
Brain (2022) Vol. 145, Iss. 12, pp. 4334-4348
Open Access | Times Cited: 82
Single-cell transcriptomics and surface epitope detection in human brain epileptic lesions identifies pro-inflammatory signaling
Pavanish Kumar, Amanda Jin Mei Lim, Sharifah Nur Hazirah, et al.
Nature Neuroscience (2022) Vol. 25, Iss. 7, pp. 956-966
Open Access | Times Cited: 81
Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target
Rongzeng Liu, Shushu Du, Lili Zhao, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 79
Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic
de Sèze, Élisabeth Maillart, Antoine Guéguen, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 69
Determinants and Biomarkers of Progression Independent of Relapses in Multiple Sclerosis
Massimiliano Calabrese, Paolo Preziosa, Antonio Scalfari, et al.
Annals of Neurology (2024) Vol. 96, Iss. 1, pp. 1-20
Open Access | Times Cited: 28
The role of Th17 cells in psoriasis
Binbin Li, Liangliang Huang, Peng Lv, et al.
Immunologic Research (2020) Vol. 68, Iss. 5, pp. 296-309
Closed Access | Times Cited: 105
The neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios are independently associated with neurological disability and brain atrophy in multiple sclerosis
Christopher C. Hemond, Bonnie I. Glanz, Rohit Bakshi, et al.
BMC Neurology (2019) Vol. 19, Iss. 1
Open Access | Times Cited: 103
The role of chemokines and chemokine receptors in multiple sclerosis
Liyuan Cui, Shifeng Chu, Naihong Chen
International Immunopharmacology (2020) Vol. 83, pp. 106314-106314
Open Access | Times Cited: 100
Pathogenic T cell cytokines in multiple sclerosis
Catriona A. Wagner, Pamela J. Roqué, Joan Goverman
The Journal of Experimental Medicine (2019) Vol. 217, Iss. 1
Open Access | Times Cited: 98
Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring
Kathy Khoy, Delphine Mariotte, Gilles Defer, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 93
Fungi as Part of the Microbiota and Interactions with Intestinal Bacteria
Mario Kapitan, Maria J. Niemiec, Alex Steimle, et al.
Current topics in microbiology and immunology (2018), pp. 265-301
Closed Access | Times Cited: 89
Human CD4+ T cell subsets differ in their abilities to cross endothelial and epithelial brain barriers in vitro
Hideaki Nishihara, Sasha Soldati, Adrien Mossu, et al.
Fluids and Barriers of the CNS (2020) Vol. 17, Iss. 1
Open Access | Times Cited: 86
Current and emerging disease‐modulatory therapies and treatment targets for multiple sclerosis
Fredrik Piehl
Journal of Internal Medicine (2020) Vol. 289, Iss. 6, pp. 771-791
Open Access | Times Cited: 78
Th17 cells and inflammation in neurological disorders: Possible mechanisms of action
Yajun Shi, Bin Wei, Lingjun Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 66
A single-cell analysis framework allows for characterization of CSF leukocytes and their tissue of origin in multiple sclerosis
Patrick Ostkamp, Marie Deffner, Andreas Schulte‐Mecklenbeck, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 673
Open Access | Times Cited: 41
DICAM promotes T H 17 lymphocyte trafficking across the blood-brain barrier during autoimmune neuroinflammation
Marc Charabati, Camille Grasmuck, Soufiane Ghannam, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 626
Closed Access | Times Cited: 39
Personalized Use of Disease-Modifying Therapies in Multiple Sclerosis
Chi‐Yan Lee, Koon‐Ho Chan
Pharmaceutics (2024) Vol. 16, Iss. 1, pp. 120-120
Open Access | Times Cited: 15
Arachidonic acid-derived lipid mediators in multiple sclerosis pathogenesis: fueling or dampening disease progression?
Jelle Y. Broos, Rianne T. M. van der Burgt, Julia Konings, et al.
Journal of Neuroinflammation (2024) Vol. 21, Iss. 1
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top